‹ All questions

How is Bristol Myers Squibb (BMY) doing?

Bristol Myers Squibb is a company in the drug manufacturers, general industry, based in Princeton, NJ, worth $120.8B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

33
P3 score

Middling

Bristol Myers Squibb shares are up 33% over the past year, 15 points ahead of the S&P 500. Its type is Speculative Pop. Among large US stocks and funds it ranks in the 83rd percentile on market beat, the 16th on staying power and the 26th on business growth. It appears on 10 of our dashboards, including 2nd on “Whose cash flow backs up their earnings?”.

$59.12+33% in a yearWorth $120.8B

Compare with MRK · LLY · ABBV · JNJ · AZN · AMGN · GILD · PFE · REGN

Financials, earnings and news on Stox ›
Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

BMY against the S&P 500, past year
$100 a year ago. Bristol Myers Squibb +33%, the S&P 500 +16%.
100120140NovDecJanFebMarAprMayJunJulAugSepOct
BMYS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Speculative Pop

BeatingErraticSlowingBought

Beating the market with buyers piling in, but erratically, and its business growth trails most.

Speculative Pop since Aug; Hot Hand before that.

Also Speculative Pop (69 in all): MTD · TMO · RPRX · DVA · BIO · A

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

BMY, past year+33%22 of 86 in the group
Rest of the group+20%equal-weighted
S&P 500+16%past year

Bristol Myers Squibb is +33% over the past year, against +20% for the rest of the group and +16% for the S&P 500. It ranks 22nd of 86 in Health care.

100120140NovDecJanFebMarAprMayJunJulAugSepOct
BMYRest of the group

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Bristol Myers Squibb typically moves 2.4% in a day, about usual for it, and it swings less than 80% of large US stocks.

Typical day2.4%about $1.40 a share
Its usual2.4%about usual, 1.0× its year’s average
Against the S&P 5002.1×the index’s typical day is 1.1%
Unusual day±4.7%twice its typical day
Deepest fall, past year−14%now 13% below its high
In the S&P’s down weeks28%of the index’s fall, three years; beta 0.2
2%2.50%NovDecJanFebMarAprMayJunJulAugSepOct
Typical daily move (ATR)Its year’s average 2.36%

BMY on our dashboards

Every question where Bristol Myers Squibb appears, in the order of the home page, with its reading and place in that table. Select a question to open it with BMY highlighted. Select a column to sort.

QuestionReadingPlaceDetails
Which stocks are analysts upgrading and downgrading?
Events
1Downgraded48 of 60Upgrades 0 · Downgrades 1 · Latest change Leerink Partners: Outperform to Market Perform, Oct 5
Who beats estimates every quarter?
Earnings
9712 in a row15 of 60Run 12 · EPS beats 12 of 12 · Sales beats 11 of 12
Which companies earn the most on their capital?
Business quality
87Excellent53 of 60Return on capital 17% · Gross margin 70% · Cash margin 23%
Whose cash flow backs up their earnings?
Business quality
99Backed2 of 603 years 300% · Last year 123% · Free cash flow $11.4B
Which companies invest the most in research?
Business quality
85Heavy29 of 60R&D / revenue 21.8% · R&D a year $10.7B · R&D, 1Y +7%
Which stocks are cheapest on cash flow?
Value
93Cheap54 of 60Cash yield 8.9% · Price / FCF 11.3× · Cash margin 23%
Which stocks are cheap against their own history?
Value
96Cheap53 of 60P/E now 13.0x · 10-yr median 25.1x · Earnings, 1Y +83%
Which stocks are cheaper than their rivals?
Value
97Cheaper13 of 60P/E 13.0x · Rivals’ P/E 34.9x · Growth gap −6 pts
Which dividends are safe?
Dividends and buybacks
19At risk79 of 80Yield 4.0% · Paid out of earnings 53% · Reliable cash 57
Where is money flowing in?
Who’s buying and selling
95Inflow26 of 6030 days 46 · 5 days 24 · Net buying +18%

Go deeper on Stox

BMY’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see BMY’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›